相关实验视频

Updated: Jun 21, 2025

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

Published on: January 10, 2025

丸激素配方对跨性别个体血红素的影响:系统性审查

Sérgio Henrique Pires Okano¹, Giordana Campos Braga², Débora Aiesha Leite Cantelli¹

¹Department of Gynecology and Obstetrics, University of São Paulo, Ribeirão Preto, Brazil.

|July 16, 2024

概括

用丸激素进行性别确认激素治疗会增加跨性别男性的血红素 (Hct). 诸如配方,吸烟和BMI等因素影响Hct水平,观察到不同的红细胞瘤风险.

科学领域:

内分泌学在内分泌学.
跨性别者健康跨性别者健康
血液学血液学血液学

背景情况:

用于性别肯定激素治疗 (GAHT) 的丸激素管理与大约11%的跨性别男性在第一年内发生红细胞瘤相关.
血红素 (Hct) 升高是疗法的已知副作用之一.

研究的目的:

为了比较不同丸激素配方对血红素 (Hct) 水平的影响.
为了确定与经过GAHT的跨性别男性的红细胞瘤诊断相关的因素.

主要方法:

在遵守PRISMA指南的基础上进行系统审查.
在2024年1月进行的PubMed,Embase和Web of Science的电子文献搜索.
使用纽卡斯尔-太华尺度进行观察性研究的质量评估.

主要成果:

注射型非酸 (TU) 增加了Hct高达5%,而中间注射型酸 (TE) 则增加了Hct高达6.9%.
使用TE的跨性别男性比使用TU的男性显示出更大的Hct增加.
红细胞瘤的患病率因切断值 (50%,52%,54%) 而异,与吸烟,治疗开始时的年龄,BMI和肺部疾病有关.
变性男性患红细胞瘤的风险比 cisgender 男性高7.4 倍 (HR 7.4,95% CI: 4.1,13.4),Hct 截止值为 52%.

结论:

所有的配方都会提高Hct,无论剂量,配方或给药方式如何.
吸烟,治疗开始时的年龄较大,BMI较高,以及先前存在的疾病与Hct.增加有关.
关于 TE 和 TU 对 Hct 的差异性影响,存在相互矛盾的结果,由于观察性,回顾性和小样本研究设计的限制.

关键词:

血红细胞结合症 (erythrocytosis) 是一种性别确认程序性别确认程序血红素的血红素值是什么多细胞性血症多细胞性血症测试剂测试剂测试剂测试剂变性人变性人变性人

更多相关视频

Combining Behavioral Endocrinology and Experimental Economics: Testosterone and Social Decision Making

Combining Behavioral Endocrinology and Experimental Economics: Testosterone and Social Decision Making

Published on: March 2, 2011

Author Spotlight: Advancing Human Ovarian Repair and Cancer Studies with Surface Epithelium Organoids

Author Spotlight: Advancing Human Ovarian Repair and Cancer Studies with Surface Epithelium Organoids

Published on: August 16, 2024

相关概念视频

Testosterone: Functions and Regulation

Testosterone: Functions and Regulation

The intricate hormonal interplay essential for male reproductive health begins with the release of gonadotropin-releasing hormone (GnRH) by the hypothalamus. This hormone prompts the pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). LH targets the Leydig cells in the testes, stimulating them to produce and release testosterone. In concert with testosterone, FSH acts on the Sertoli cells within the seminiferous tubules to facilitate the release of...

Hormonal Regulation of Blood Pressure

Hormonal Regulation of Blood Pressure

Endocrinal or hormonal intervention in the cardiovascular system is predominantly exerted by the catecholamines - epinephrine and norepinephrine, as well as a slew of hormones that interact with renal function to modulate blood volume.
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction...

Signs of Puberty

Signs of Puberty

Puberty is a critical phase, typically beginning between the ages of 8 and 13 in girls and 9 and 14 in boys, though timing can vary based on genetics, environmental factors, and overall health. This period is characterized by the development of secondary sexual characteristics and the attainment of reproductive potential. Endocrine changes underpin puberty, with hormonal surges of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) instigated by Gonadotropin-Releasing Hormone (GnRH)...

Disorders of the Male Reproductive System

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....